Publications 2025
Lysa
2025_Are oldest old patients with diffuse large B-cell lymphoma different than their younger counterparts: Results from the REALYSA real-life cohort
Cancer Epidemiol 2025;96:102812
En savoir plus
Lysa
2025_Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study
Nat Cancer 2025;:
En savoir plus
Lysa
2025_High-dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited-stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial
Hemasphere 2025;9:e70105
En savoir plus
Lysa
2025_Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA
EClinicalMedicine 2025;82:103157
En savoir plus
Lysa
2025_Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines
Eur J Cancer 2025;220:115369
En savoir plus
Lysa
2025_Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials
Eur J Nucl Med Mol Imaging 2025;:
En savoir plus
Lysa
2025_A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis
Br J Haematol 2025;:
En savoir plus
Lysa
2025_Interim PET after 4 Cycles Predicts Outcome in Histomolecularly Confirmed Primary Mediastinal B-Cell Lymphoma
Blood Adv 2025;:bloodadvances.2024015577
En savoir plus
Lysa
2025_PET-based lesion graphs meet clinical data: An interpretable cross-attention framework for DLBCL treatment response prediction
Computerized Medical Imaging and Graphics 2025;120:102481
En savoir plus
Lysa
2025_Personalized baseline and residual TMTV influence treatment response and outcomes in relapsed/refractory lymphomas: results from the GATA study
Eur J Nucl Med Mol Imaging 2025;:
En savoir plus
Lysa
2025_Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry
Hemasphere 2025;9:e70091
En savoir plus
Lysa
2025_Outcome of high-grade B-cell lymphoma compared to other large B-cell lymphoma after CAR-T rescue. A DESCAR-T LYSA study
Blood Adv 2025;:bloodadvances.2024014732
En savoir plus
Lysa
2025_T cell malignancies after CAR T cell therapy in the DESCAR-T registry
Nat Med 2025;:
En savoir plus
Publications 2024
Lysa
2024_Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significance
Blood 2024;144:2503-2516
En savoir plus
Lysa
2024_Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines
European Journal of Cancer 2024;213:115073
En savoir plus
Lysa
2024_Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
Blood Cancer J 2024;14:197
En savoir plus
Lysa
2024_Precautions to Consider in the Analysis of Prognostic and Predictive Indices
2024;65:1672-1678
En savoir plus
Lysa
2024_Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study
Hematol Oncol 2024;42:e3314
En savoir plus
Lysa
2024_Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials
J Cancer Surviv 2024;:
En savoir plus
Lysa
2024_A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel versus Tisagenlecleucel in the Treatment of Diffuse Large B-cell Lymphoma Based on a Real-World French Registry
Adv Ther 2024;:
En savoir plus
Lysa
2024_Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5′ RACE
Blood Adv 2024;:bloodadvances.2024013723
En savoir plus
Lysa
2024_Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)
J Clin Oncol 2024;:JCO2400554
En savoir plus
Lysa
2024_MYC Rearrangement Prediction from LYSA Whole Slide Images in Large B-cell Lymphoma: A Multi-centric Validation of Self-supervised Deep Learning Models
Mod Pathol 2024;:100610
En savoir plus
Lysa
2024_International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline 18F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation
J Nucl Med 2024;65:1343-1348
En savoir plus
Lysa
2024_Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort
Eur J Cancer 2024;208:114210
En savoir plus
Lysa
2024_Efficacy and Tolerance of Brexucabtagene Autoleucel in Adults with R/R B-ALL : A GRAALL study from the DESCAR-T registry
Blood Advances 2024;:bloodadvances.2024013962
En savoir plus
Lysa
2024_Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells
Blood Adv 2024;:bloodadvances.2024013726
En savoir plus
Lysa
2024_Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration
Leukemia 2024;:
En savoir plus
Lysa
2024_CAR T-cells in very elderly (≥80 years) lymphoma patients: a DESCAR-T analysis
Leuk Lymphoma 2024;:1-4
En savoir plus
Lysa
2024_Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
J Hematol Oncol 2024;17:61
En savoir plus
Lysa
2024_IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma
Haematologica 2024;109:2564-2573
En savoir plus
Lysa
2024_Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma
Blood 2024;144:262-271
En savoir plus
Lysa
2024_Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma
Blood 2024;144:334-338
En savoir plus
Lysa
2024_Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital
Hematol Oncol 2024;42:e3297
En savoir plus
Lysa
2024_High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia
Blood 2024;143:2804-2807
En savoir plus
Lysa
2024_Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry
Haematologica 2024;:
En savoir plus
Lysa
2024_Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group
Haematologica 2024;109:1857-1865
En savoir plus
Lysa
2024_Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study
Lancet Haematol 2024;11:e406-e414
En savoir plus
Lysa
2024_French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry
Br J Haematol 2024;:
En savoir plus
Lysa
2024_Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial
J Clin Oncol 2024;42:1612-1618
En savoir plus
Lysa
2024_Lymphoma in Patients with Inflammatory Bowel Disease: A Multicentre Collaborative Study Between GETAID and LYSA
J Crohns Colitis 2024;18:533-539
En savoir plus
Lysa
2024_Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)
Blood Adv 2024;8:1573-1585
En savoir plus
Lysa
2024_The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients
Blood 2024;143:983-995
En savoir plus
Lysa
2024_Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study
J Clin Oncol 2024;42:769-773
En savoir plus
Lysa
2024_Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial
JCO 2024;42:538-549
En savoir plus
Lysa
2024_Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial
2024;65:313-319
En savoir plus
Lysa
2024_Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy
Blood 2024;143:422-428
En savoir plus
Lysa
2024_Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort
Blood Advances 2024;8:296-308
En savoir plus
Lysa
2024_Prognostic Value of 18F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study
2024;65:156-162
En savoir plus
Lysa
2024_Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial☆
Annals of Oncology 2024;35:130-137
En savoir plus
Lysa
2024_Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma
JCO 2024;42:19-25
En savoir plus
Lysa
2024_Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling
2024;625:778-787
En savoir plus
Lysa
2024_Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma—Final Analysis
2024;16:2672
En savoir plus
Lysa
2024_Prognostic Value of Baseline Tumor Burden and Tumor Dissemination Extracted From 18F-FDG PET/CT in a Cohort of Adult Patients With Early or Advanced Hodgkin Lymphoma
2024;49:e1
En savoir plus
Publications 2023
Lysa
2023_Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy
Haematologica 2023;108:3433-3437
En savoir plus
Lysa
2023_Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX
Clin Transl Sci 2023;16:2744-2755
En savoir plus
Lysa
2023_Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
Blood Adv 2023;7:6589-6598
En savoir plus
Lysa
2023_Outcomes of High-Grade B-Cell Lymphoma As Compared to Other Large B-Cell Lymphoma Subtypes in Patients Treated with CD19-Directed CAR-T Cells at 3 rd Line or More. a Lysa Study Based on the French Descart-Registry.
Blood 2023;142:3112
En savoir plus
Lysa
2023_CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma
Blood 2023;142:1543-1555
En savoir plus
Lysa
2023_Validation of the ΔSUVmax for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial
J Nucl Med 2023;64:1706-1711
En savoir plus
Lysa
2023_Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial
Sci Rep 2023;13:18177
En savoir plus
Lysa
2023_Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
Nat Med 2023;29:2593-2601
En savoir plus
Lysa
2023_Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)
Leukemia 2023;37:1887-1894
En savoir plus
Lysa
2023_Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
Lancet Haematol 2023;10:e624-e632
En savoir plus
Lysa
2023_Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany
Br J Haematol 2023;202:771-775
En savoir plus
Lysa
2023_Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen
Br J Haematol 2023;202:686-689
En savoir plus
Lysa
2023_Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514)
Eur J Cancer 2023;189:112909
En savoir plus
Lysa
2023_Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group
Blood Adv 2023;7:3735-3738
En savoir plus
Lysa
2023_Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study
J Clin Oncol 2023;41:3523-3533
En savoir plus
Lysa
2023_Work and education interruption in long-term Hodgkin lymphoma survivors: an analysis among patients from nine EORTC-LYSA trials
Acta Oncol 2023;62:744-752
En savoir plus
Lysa
2023_Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA
Br J Haematol 2023;202:379-383
En savoir plus
Lysa
2023_The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity
Clin Cancer Res 2023;29:2280-2290
En savoir plus
Lysa
2023_Lack of reproducibility of histopathological features in MYC-rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium
Histopathology 2023;82:1105-1111
En savoir plus
Lysa
2023_Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial
Blood 2023;141:1971-1981
En savoir plus
Lysa
2023_Exploring the genetic landscape of HCV-related B-cell lymphomas using whole exome sequencing
Leukemia 2023;37:1388-1391
En savoir plus
Lysa
2023_Real-world Experience of Approved Chimeric Antigen Receptor T-cell Therapies Compared to Clinical Trials Data
2023;7:e873
En savoir plus
Lysa
2023_Dissemination patterns of Hodgkin lymphoma using a probability network model based on [18F]-FDG PET/CT
Eur J Nucl Med Mol Imaging 2023;50:1414-1422
En savoir plus
Lysa
2023_Données et preuves en vie réelle dans l’évaluation des technologies de santé : dans quels cas sont-elles complémentaires, substitutives, ou les seules sources de données par rapport aux essais cliniques ?
2023;78:
En savoir plus
Lysa
2023_Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment
Hemasphere 2023;7:e863
En savoir plus
Lysa
2023_Do we have to exclude all relapsed diffuse large B-cell lymphoma patients not in complete remission from autologous stem cell transplant?
Br J Haematol 2023;200:13-14
En savoir plus
Lysa
2023_Long-term excess mortality and net survival among elderly diffuse large B-cell lymphoma patients after front-line R-CHOP treatment
Br J Haematol 2023;201:857-864
En savoir plus
Lysa
2023_Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study
Br J Haematol 2023;201:256-266
En savoir plus
Lysa
2023_How molecular advances may improve the diagnosis and management of PTCL patients
Front Oncol 2023;13:1202964
En savoir plus
Lysa
2023_High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma
Blood Adv 2023;7:7331-7345
En savoir plus
Lysa
2023_Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells
Haematologica 2023;108:171-180
En savoir plus
Lysa
2023_LYSA_Randomized Phase III Trial Evaluating Sub-Cutaneous Rituximab for the First Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study
J Clin Oncol . 2023 Apr 18;JCO2202327. doi: 10.1200/JCO.22.02327.
En savoir plus
Lysa
2023_LYSA_High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network
DOI: 10.1200/JCO.22.01780
En savoir plus
Lysa
2023_LYSA_Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome
DOI: 10.3324/haematol.2022.281226
En savoir plus
Lysa
2023_LYSA_Central nervous system relapse in younger patients with diffuse large B-cell lymphoma – a LYSA and GLA/ DSHNHL analysis
doi: 10.1182/bloodadvances.2022008888.
En savoir plus
Publications 2022
Lysa
2022_LYSA_From Stem Cell Transplantation to CAR-T Therapy in Relapse-Refractory Diffuse Large B-Cell Lymphoma
doi.org/10.18103/mra.v10i8.3014
En savoir plus
Lysa
2022_LYSA_Do we have to exclude all relapsed diffuse large B-cell lymphoma patients not in complete remission from autologous stem cell transplant?
doi: 10.1111/bjh.18468
En savoir plus
Lysa
2022_LYSA_Outcomes of patients with aggressive B-Cell lymphoma after failure of anti-CD19 CAR T-Cell Therapy. A DESCAR-T analysis
doi: 10.1182/blood.2022016945.
En savoir plus
Calym
HemSys_Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase
Leukemia & Lymphoma, 59:12, 2812-2820, DOI: 10.1080/10428194.2018.1441408
En savoir plus
Calym
HemSys_IGHV segment utilization in immunoglobulin gene rearrangement differentiates patients with anti-myelin-associated glycoprotein neuropathy from others immunoglobulin M-gammopathies
Haematologica 2018;103(5):e207-e210; https://doi.org/10.3324/haematol.2017.177444.
En savoir plus
Calym
HemSys_Diagnostic value of 18-F fluorodeoxyglucose PET/CT and bone scan in Schnitzler syndrome
Autoimmunity, 52:7-8, 264-271, DOI: 10.1080/08916934.2019.1680649
En savoir plus
Calym
HemSys_Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)
Br J Haematol, 179: 439-448. https://doi.org/10.1111/bjh.14881
En savoir plus
HemSys_Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study
Oncotarget. 2016; 7: 85573-85583. Retrieved from https://www.oncotarget.com/article/10764/text/
En savoir plus
Calym
HemSys_Switches of tyrosine-kinase inhibitors in chronic phase of chronic myeloid leukemia in real life
Am J Hematol, 93: E329-E331. https://doi.org/10.1002/ajh.25217
En savoir plus
Calym
HemSys_Impact of High-Dose Methotrexate on the Outcome of Patients with Diffuse Large B-Cell Lymphoma and Skeletal Involvement
Cancers 2021, 13(12), 2945; https://doi.org/10.3390/cancers13122945
En savoir plus
Calym
HemSys_Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network
Neuro-Oncology, Volume 18, Issue 9, September 2016, Pages 1297–1303, https://doi.org/10.1093/neuonc/now033
En savoir plus
Calym
HemSys_Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study
Leukemia & Lymphoma, 56:7, 2025-2031, DOI: 10.3109/10428194.2014.977884
En savoir plus
Lysa
2022_LYSA_A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
doi: 10.1038/s41591-022-01969-y.
En savoir plus
Lysa
2022_LYSA_PET-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T-cells
doi: 10.3324/haematol.2021.280550.
En savoir plus
Lysa
2022_LYSA_Interpretation of 2-[ 18 F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors
Eur Radiol . 2022 Sep;32(9):6536-6544.
En savoir plus
Lysa
2022_LYSA_Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations
Mod Pathol . 2022 Aug;35(8):1126-1136.
En savoir plus
Lysa
2022_LYSA_Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA)
Br J Haematol . 2022 Jul;198(1):203-206.
En savoir plus
Lysa
2022_LYSA_Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study
Haematologica . 2022 Jul 1;107(7):1681-1686.
En savoir plus
Lysa
2022_LYSA_Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with Mantle Cell lymphoma, a LYSA retrospective study
Bone Marrow Transplant . 2022 Apr;57(4):627-632.
En savoir plus
Lysa
2022_LYSA_The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma
Blood . 2022 Jan 20;139(3):384-398.
En savoir plus
Lysa
2022_LYSA_Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study
doi: 10.1080/10428194.2022.2107204.
En savoir plus
Lysa
2022_LYSA_Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
J Clin Oncol . 2022 Aug 10;JCO2200843.
En savoir plus
Lysa
2022_LYSA_Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial
doi: 10.1200/JCO.21.01281.
En savoir plus
Lysa
2022_LYSA_High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline
doi: 10.3324/haematol.2021.280004
En savoir plus
Lysa
2022_LYSA_Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial
10.1182/bloodadvances.2022007609.
En savoir plus
Lysa
2022_Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes
Leukemia 2022;36:2835-2844
En savoir plus
Lysa
2022_Mature T-cell neoplasms and stem cell transplant: the never-ending story
Haematologica 2022;107:2534-2535
En savoir plus
Lysa
2022_Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study
J Nucl Med 2022;63:1149-1154
En savoir plus
Lysa
2022_LYSA_Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation
Am J Surg Pathol 2022;46:742-753
En savoir plus
Lysa
2022_LYSA_Oncogenetic landscape of lymphomagenesis in coeliac disease
Gut . 2022 Mar;71(3):497-508.
En savoir plus
Lysa
2022_LYSA_PET-driven strategy in advanced Hodgkin lymphoma: prolonged follow-up of the AHL2011 Phase III LYSA study
J Clin Oncol . 2022 Apr 1;40(10):1091-1101.
En savoir plus
Lysa
2022_LYSA_Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases
J Oncol Pharm Pract . 2022 Mar;28(2):453-456.
En savoir plus
Lysa
2022_LYSA_Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in FL from 5,225 Patients on 13 Clinical Trials
Blood . 2022 Mar 17;139(11):1684-1693.
En savoir plus
Lysa
2022_LYSA_A guide to ComBat harmonization of imaging biomarkers in multicenter studies
J Nucl Med . 2022 Feb;63(2):172-179.
En savoir plus
Lysa
2022_LYSA_Deep Learning approach to automatize TMTV calculation regardless of segmentation methodology for main FDG avid lymphomas
Diagnostics (Basel) . 2022 Feb 6;12(2):417.
En savoir plus
Lysa
2022_LYSA_Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
Hemasphere . 2022 Jan 10;6(2):e672.
En savoir plus
Lysa
2022_LYSA_Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study
Ann Hematol . 2022 Feb;101(2):317-332.
En savoir plus
Lysa
2022_LYSA_Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group
Cancers (Basel) 2022 Mar 30;14(7):1761. doi: 10.3390/cancers14071761.
En savoir plus
Lysa
2022_LYSA_Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study
Cancer . 2022 Feb 1;128(3):519-528. doi: 10.1002/cncr.33938.
En savoir plus
Lysa
2022_LYSA_Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
J Clin Oncol . 2022 Jan 20;40(3):242-251. doi: 10.1200/JCO.21.01815.
En savoir plus
Lysa
2022_LYSA_Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
N Engl J Med . 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304.
En savoir plus
Lysa
2022_LYSA_Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA
DOI: 10.1182/bloodadvances.2022008524
En savoir plus
Lysa
2022_LYSA_Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials
DOI: 10.1111/bjh.18594
En savoir plus
Lysa
2022_LYSA_ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study
DOI: 10.3324/haematol.2022.281442
En savoir plus
Lysa
2022_LYSA_Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials
DOI: 10.1007/s11764-022-01305-w
En savoir plus
Lysa
2022_LYSA_Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study
DOI: 10.1111/bjh.18519
En savoir plus
Lysa
2022_LYSA_Molecular Monitoring of Lymphomas
DOI: 10.1146/annurev-pathol-050520-044652
En savoir plus
Lysa
2022_LYSA_European Association of Neuro-Oncology (EANO) Guidelines for Treatment of Primary Central Nervous System lymphoma (PCNSL)
DOI: 10.1093/neuonc/noac196
En savoir plus
Lysa
2022_LYSA_Application of The Lugano Classification for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2- Technical)
DOI: 10.2967/jnumed.122.264124
En savoir plus
Lysa
2022_LYSA_Application of The Lugano Classification for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1- Clinical)
DOI: 10.2967/jnumed.122.264106
En savoir plus
Lysa
2022_LYSA_Influence of Sociodemographic Determinants on the Hodgkin Lymphoma Baseline Characteristics in Long Survivors Patients Enrolled in the Prospective Phase 3 Trial AHL2011
doi: 10.3390/cancers15010053
En savoir plus
Lysa
2022_LYSA_Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France
DOI: 10.1016/j.eclinm.2022.101674
En savoir plus
Lysa
2022_LYSA_Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
DOI: 10.1038/s41375-022-01717-8
En savoir plus
Lysa
2022_LYSA_18F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients
DOI: 10.2967/jnumed.121.263501
En savoir plus
Lysa
2022_LYSA_A tumor volume and performance status model to predict outcome prior to treatment in diffuse large B-cell lymphoma
DOI: 10.1182/bloodadvances.2021006923
En savoir plus
Lysa
2022_LYSA_Finding a consensus on time-to-event endpoints definitions in marginal zone lymphoma: A Delphi method
DOI: 10.1002/hon.2988
En savoir plus
Lysa
2022_LYSA_Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma
DOI: 10.1002/ajh.26715
En savoir plus
Lysa
2022_LYSA_Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study
DOI: 10.1080/0284186X.2022.2130709
En savoir plus
Lysa
2022_LYSA_Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak
DOI: 10.1080/10428194.2022.2086249
En savoir plus
Lysa
2022_LYSA_Genomic profiling for clinical decision making in lymphoid neoplasms
DOI: 10.1182/blood.2022015854
En savoir plus
Lysa
2022_LYSA_Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population
DOI: 10.1016/j.ejca.2022.08.019
En savoir plus
Lysa
2022_LYSA_Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study
DOI: 10.1002/hon.3025
En savoir plus
Lysa
2022_LYSA_Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper
DOI: 10.1002/hon.3013
En savoir plus
Lysa
2022_LYSA_Prognostic value of FDG‐PET/CT response for patient selection before chimeric antigen receptor‐T‐cells therapy in non‐Hodgkin lymphoma
DOI: 10.1002/hon.2965
En savoir plus
Lysa
2022_LYSA_Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study
DOI: 10.1002/cam4.4742
En savoir plus
Lysa
2022_LYSA_Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
DOI: 10.1182/bloodadvances.2022008355
En savoir plus
Lysa
2022_LYSA_The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
DOI: 10.1182/blood.2022015851
En savoir plus
Lysa
2022_LYSA_Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
DOI: 10.1182/bloodadvances.2022007371
En savoir plus
Lysa
2022_LYSA_Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma
DOI: 10.3324/haematol.2021.279561
En savoir plus
Lysa
2022_LYSA_The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
DOI: 10.1038/s41375-022-01620-2
En savoir plus
Lysa
2022_LYSA_End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma
DOI: 10.1111/bjh.18217
En savoir plus
Lysa
2022_LYSA_Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials
DOI: 10.1080/10428194.2022.2032038
En savoir plus
Lysa
2022_LYSA_Chemotherapy-free treatment in unfit patients aged 75 years and older with DLBCL: toward a new paradigm?
DOI: 10.1016/S2666-7568(22)00150-7
En savoir plus
Lysa
2022_LYSA_Peripheral T-Cell Lymphomas: Therapeutic Approaches
DOI: 10.3390/cancers14092332
En savoir plus
Lysa
2022_LYSA_The EHA Research Roadmap: Malignant Lymphoid Diseases
DOI: 10.1097/HS9.0000000000000726
En savoir plus
Lysa
2022_LYSA_Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality
DOI: 10.3390/cancers14102392
En savoir plus
Lysa
2022_LYSA_Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients
DOI: 10.1182/blood.2021014506
En savoir plus
Lysa
2022_LYSA_The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target‑Mediated Drug Disposition
DOI: 10.1007/s40262-021-01081-3
En savoir plus
Lysa
2022_LYSA_Chapter 22: Bridging Chemotherapy: Relapsed/Refractory Aggressive B-Cell Lymphoma
DOI: 10.1007/978-3-030-94353-0_22
En savoir plus
Lysa
2022_LYSA_Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
DOI: 10.1097/HS9.0000000000000675
En savoir plus
Lysa
2022_LYSA_What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts
DOI: 10.1097/HS9.0000000000000680
En savoir plus
Lysa
2022_LYSA_PET imaging: back in the game for gastric EMZL?
doi: 10.1182/blood.2021013964.
En savoir plus
Lysa
2022_LYSA_Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study
J Clin Oncol 2022 Jan 6;JCO2101777. doi: 10.1200/JCO.21.01777
En savoir plus
Lysa
2022_LYSA_Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy
Blood . 2022 Apr 14;139(15):2338-2346.
En savoir plus